Grigorios Siokas Purchases 766,284 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas purchased 766,284 shares of the stock in a transaction dated Wednesday, July 29th. The shares were bought at an average cost of $0.18 per share, for a total transaction of $137,931.12. Following the completion of the purchase, the chief executive officer owned 14,248,092 shares in the company, valued at approximately $2,564,656.56. This trade represents a 5.68% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Thursday, July 30th, Grigorios Siokas acquired 349,825 shares of Cosmos Health stock. The stock was bought at an average price of $0.20 per share, with a total value of $69,965.00.
• On Thursday, June 11th, Grigorios Siokas acquired 218,447 shares of Cosmos Health stock. The stock was bought at an average price of $0.21 per share, with a total value of $45,873.87.
• On Wednesday, June 10th, Grigorios Siokas acquired 701,447 shares of Cosmos Health stock. The shares were bought at an average cost of $0.23 per share, for a total transaction of $161,332.81.

Cosmos Health Trading Up 7.7%

Shares of COSM opened at $0.22 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.92 and a debt-to-equity ratio of 0.31. The firm’s 50-day moving average is $0.23 and its two-hundred day moving average is $0.33. Cosmos Health Inc. has a twelve month low of $0.16 and a twelve month high of $1.32. The firm has a market capitalization of $12.94 million, a P/E ratio of -0.34 and a beta of 4.83.

Cosmos Health (NASDAQ:COSM) last issued its earnings results on Wednesday, May 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. The company had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $17.93 million. On average, research analysts predict that Cosmos Health Inc. will post 0.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cosmos Health currently has an average rating of “Sell”.

Institutional Investors Weigh In On Cosmos Health

Several institutional investors and hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC grew its stake in Cosmos Health by 133.1% in the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after acquiring an additional 128,776 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Cosmos Health by 260.5% during the 4th quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock valued at $167,000 after acquiring an additional 241,775 shares in the last quarter. Finally, XTX Topco Ltd raised its position in Cosmos Health by 52.1% during the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after acquiring an additional 34,117 shares during the last quarter. 12.61% of the stock is currently owned by hedge funds and other institutional investors.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.